{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:19:55Z","timestamp":1787685595810,"version":"build-2784847793"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Routine to research","award":["R016535016"],"award-info":[{"award-number":["R016535016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00159-w","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:09:17Z","timestamp":1787641757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neutropenia in adult patients with thalassemia receiving deferiprone: a 10-year experience from a large thalassemia cohort"],"prefix":"10.1007","volume":"61","author":[{"given":"Ploylarp","family":"Lertvipapath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weerapat","family":"Owatanapanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waratchaya","family":"Uawattanasakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smith","family":"Kungwankiattichai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"1","key":"159_CR1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2017.018","volume":"9","author":"V De Sanctis","year":"2017","unstructured":"De Sanctis V, Kattamis C, Canatan D, et al. \u03b2-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediterr J Hematol Infect Dis. 2017;9(1):e2017018.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"159_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/03630269.2022.2025824","volume":"46","author":"K Paiboonsukwong","year":"2022","unstructured":"Paiboonsukwong K, Jopang Y, Winichagoon P, et al. Thalassemia in Thailand. Hemoglobin. 2022;46(1):53\u20137.","journal-title":"Hemoglobin"},{"issue":"1","key":"159_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/nyas.13026","volume":"1368","author":"D Auger","year":"2016","unstructured":"Auger D, Pennell DJ. Cardiac complications in thalassemia major. Ann N Y Acad Sci. 2016;1368(1):56\u201364.","journal-title":"Ann N Y Acad Sci"},{"issue":"22","key":"159_CR4","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMra1800219","volume":"379","author":"RC Hider","year":"2018","unstructured":"Hider RC, Hoffbrand AV. The role of deferiprone in iron chelation. N Engl J Med. 2018;379(22):2140\u201350.","journal-title":"N Engl J Med"},{"issue":"6","key":"159_CR5","doi-asserted-by":"publisher","first-page":"e402","DOI":"10.1097\/MPH.0000000000002894","volume":"46","author":"TT Sari","year":"2024","unstructured":"Sari TT, Wahidiyat PA, Rahmartani LD, et al. Comparison of yearly cost related to complications between deferasirox and deferiprone monotherapy in thalassemia. J Pediatr Hematol Oncol. 2024;46(6):e402\u20135.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"159_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1310\/hpj4702-129","volume":"47","author":"DJ Cada","year":"2012","unstructured":"Cada DJ, Levien TL, Baker DE. Deferiprone. Hosp Pharm. 2012;47(2):129\u201336.","journal-title":"Hosp Pharm"},{"issue":"1","key":"159_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1600-0609.2006.00773.x","volume":"78","author":"E Vlachaki","year":"2007","unstructured":"Vlachaki E, Ioannidou Papagiannaki E, Tziomalos K, et al. Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy. Eur J Haematol. 2007;78(1):48\u201351.","journal-title":"Eur J Haematol"},{"issue":"21","key":"159_CR8","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1182\/bloodadvances.2023012316","volume":"8","author":"SM Badawy","year":"2024","unstructured":"Badawy SM, Palmblad J, Tricta F, et al. Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data. Blood Adv. 2024;8(21):5641\u20139.","journal-title":"Blood Adv"},{"issue":"10","key":"159_CR9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ajh.24479","volume":"91","author":"F Tricta","year":"2016","unstructured":"Tricta F, Uetrecht J, Galanello R, et al. Deferiprone\u2010induced agranulocytosis: 20 years of clinical observations. Am J Hematol. 2016;91(10):1026\u201331.","journal-title":"Am J Hematol"},{"issue":"5","key":"159_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/qjmed\/hcw220","volume":"110","author":"E Andr\u00e8s","year":"2017","unstructured":"Andr\u00e8s E, Mourot-Cottet R, Maloisel F, et al. Idiosyncratic drug-induced neutropenia and agranulocytosis. QJM. 2017;110(5):299\u2013305.","journal-title":"QJM"},{"issue":"30","key":"159_CR11","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043\u201354.","journal-title":"J Clin Oncol"},{"issue":"3","key":"159_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40264-023-01380-7","volume":"47","author":"E Coz","year":"2024","unstructured":"Coz E, Fauvernier M, Maucort-Boulch D. An overview of regression models for adverse events analysis. Drug Saf. 2024;47(3):205\u201316.","journal-title":"Drug Saf"},{"issue":"12","key":"159_CR13","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","volume":"24","author":"B Klimm","year":"2013","unstructured":"Klimm B, Goergen H, Fuchs M, et al. Impact of risk factors on outcomes in early-stage Hodgkin\u2019s lymphoma: an analysis of international staging definitions. Ann Oncol. 2013;24(12):3070\u20136.","journal-title":"Ann Oncol"},{"issue":"12","key":"159_CR14","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/sim.4780081211","volume":"8","author":"I Annesi","year":"1989","unstructured":"Annesi I, Moreau T, Lellouch J. Efficiency of the logistic regression and Cox proportional hazards models in longitudinal studies. Stat Med. 1989;8(12):1515\u201321.","journal-title":"Stat Med"},{"issue":"24","key":"159_CR15","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1002\/sim.2687","volume":"25","author":"G Heinze","year":"2006","unstructured":"Heinze G. A comparative investigation of methods for logistic regression with separated or nearly separated data. Stat Med. 2006;25(24):4216\u201326.","journal-title":"Stat Med"},{"key":"159_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v098.i11","volume":"98","author":"C Thiele","year":"2021","unstructured":"Thiele C, Hirschfeld G. Cutpointr: improved estimation and validation of optimal cutpoints in R. J Stat Softw. 2021;98:1\u201327.","journal-title":"J Stat Softw"},{"issue":"12","key":"159_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122778","volume":"18","author":"R Bou-Fakhredin","year":"2017","unstructured":"Bou-Fakhredin R, Bazarbachi A-H, Chaya B, et al. Iron overload and chelation therapy in non-transfusion dependent thalassemia. Int J Mol Sci. 2017;18(12):2778.","journal-title":"Int J Mol Sci"},{"key":"159_CR18","first-page":"21","volume-title":"Stephen's detection and evaluation of adverse drug reactions: principles and practice","author":"J Aronson","year":"2012","unstructured":"Aronson J. Adverse drug reactions: history, terminology, classification, causality, frequency, preventability. In: Talbot J, Aronson J, editors. Stephen\u2019s detection and evaluation of adverse drug reactions: principles and practice. Sixth ed. Oxford, United Kingdom: John Wiley & Sons, Ltd.; 2012. p. 21.","edition":"Sixth ed"},{"key":"159_CR19","first-page":"187","volume":"9","author":"E Andr\u00e8s","year":"2018","unstructured":"Andr\u00e8s E, Mourot-Cottet R. Idiosyncratic drug-induced severe neutropenia and agranulocytosis: state of the art. Hematol-Latest Res Clin Adv. 2018;9:187\u201399.","journal-title":"Hematol-Latest Res Clin Adv"},{"issue":"5","key":"159_CR20","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/pbc.24920","volume":"61","author":"M Elalfy","year":"2014","unstructured":"Elalfy M, Wali YA, Qari M, et al. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis. Pediatr Blood Cancer. 2014;61(5):879\u201384.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"159_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3109\/03630269.2010.484791","volume":"34","author":"C Pontikoglou","year":"2010","unstructured":"Pontikoglou C, Papadaki HA. Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. Hemoglobin. 2010;34(3):291\u2013304.","journal-title":"Hemoglobin"},{"issue":"1","key":"159_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/eb-2012-100645","volume":"18","author":"M Power","year":"2013","unstructured":"Power M, Fell G, Wright M. Principles for high-quality, high-value testing. Evid Based Med. 2013;18(1):5\u201310.","journal-title":"Evid Based Med"},{"issue":"1","key":"159_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1749-6632.2010.05586.x","volume":"1202","author":"A Piga","year":"2010","unstructured":"Piga A, Roggero S, Salussolia I, et al. Deferiprone. Ann N Y Acad Sci. 2010;1202(1):75\u20138.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"159_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08104.x","volume":"150","author":"E Andr\u00e8s","year":"2010","unstructured":"Andr\u00e8s E, Maloisel F, Zimmer J. The role of haematopoietic growth factors granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor in the management of drug induced agranulocytosis. Br J Haematol. 2010;150(1):3\u20138.","journal-title":"Br J Haematol"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00159-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00159-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00159-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:03:16Z","timestamp":1787684596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00159-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["159"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00159-w","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"11 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Siriraj Institutional Review Board of the Faculty of Medicine, Siriraj Hospital, Mahidol University (Certificate of Approval number: si 826\/2564 (IRB4)].","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"46"}}